Assessing eligibility for differentiated service delivery, HIV services utilization and virologic outcomes of adult HIV-infected patients in Sierra Leone: a pre-implementation analysis

ABSTRACT Background There are limited data to help guide implementation of differentiated HIV service delivery (DSD) in resource-limited settings in sub-Saharan Africa. Objectives This pre-implementation study sought to assess the proportion of patients eligible for DSD and HIV services utilization, as well as risk factor analysis of virologic failure in Sierra Leone. Methods We conducted a retrospective study of adult HIV-infected patients aged 18 years and older receiving care at the largest HIV treatment center in Sierra Leone 2019–2020. Multiple logistic regression was used to identify predictors of virologic failure. Results Of 586 unique patients reviewed, 210 (35.8%) qualified as ‘stable’ for antiretroviral therapy (ART) delivery. There was high utilization of certain HIV service programs (e.g. HIV status disclosure to partners (83%) and treatment ‘buddy’ program participation (62.8%)), while other service programs (e.g. partner testing and community HIV support group participation) had low utilization (<50%). Of 429 patients with available viral load, 277 (64.6%) were virologically suppressed. In the multivariate logistic regression analysis of risk factors of virologic failure, CD4 < 350 cells/mm3 (p = 0.009), atazanavir-based ART (p = 0.032), once monthly versus once two- or three-monthly ART dispensing (p = 0.028), history of ART switching (p = 0.02), poor adherence (p = 0.001) and not having received adherence support (p < 0.001) were independent predictors of virologic failure. Conclusion Approximately one in three HIV-infected patients on ART were eligible for DSD. We identified gaps in HIV care (i.e. low partner testing, treatment ‘buddy’, program participation and a substantially high rate of virologic failure) that need to be addressed in preparation for full implementation of DSD in Sierra Leone.

[1]  L. Wilkinson,et al.  The time is now: expedited HIV differentiated service delivery during the COVID‐19 pandemic , 2020, Journal of the International AIDS Society.

[2]  Zumbe Siwale,et al.  Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. , 2019, AIDS.

[3]  E. Poveda,et al.  Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study , 2019, BMC Public Health.

[4]  H. Wurie,et al.  A cross-sectional study on caregivers’ perspective of the quality of life and adherence of paediatric HIV patients to highly active antiretroviral therapy , 2019, BMC Pediatrics.

[5]  E. Poveda,et al.  Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone , 2019, The Journal of antimicrobial chemotherapy.

[6]  E. Poveda,et al.  HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic. , 2019, AIDS reviews.

[7]  E. Poveda,et al.  High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone , 2018, Open forum infectious diseases.

[8]  G. Kwakye-Nuako,et al.  Immunologic and virological response to ART among HIV infected individuals at a tertiary hospital in Ghana , 2018, BMC Infectious Diseases.

[9]  A. Tsai,et al.  Community-Level HIV Stigma as a Driver for HIV Transmission Risk Behaviors and Sexually Transmitted Diseases in Sierra Leone: A Population-Based Study , 2017, Journal of acquired immune deficiency syndromes.

[10]  E. Delaporte,et al.  Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis , 2017, PloS one.

[11]  P. Kanki,et al.  Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria , 2016, PloS one.

[12]  K. Bonner,et al.  Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Kantor,et al.  The centrality of laboratory services in the HIV treatment and prevention cascade: The need for effective linkages and referrals in resource-limited settings. , 2014, AIDS patient care and STDs.

[14]  W. Blattner,et al.  Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria , 2013, BMC Infectious Diseases.

[15]  J. Nachega,et al.  HIV treatment adherence, drug resistance, virologic failure: Evolving concepts , 2022 .

[16]  A. Tsai,et al.  Proximate Context of HIV Stigma and Its Association with HIV Testing in Sierra Leone: A Population-Based Study , 2015, AIDS and Behavior.

[17]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.